Myeloproliferative disorders with translocations of chromosome 5q31-35: Role of the platelet-derived growth factor receptor beta

Acta Haematologica

Volumn 107, Issue 2, 2002, Pages 113-122

  Steer, E Joanna ^a   Cross, Nicholas C P ^a  

^a SALISBURY DISTRICT HOSPITAL   (United Kingdom)

Author keywords

5q31; 5q33; Eosinophilia; Myeloproliferative disorder; PDGFRB

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURVIVAL; CHROMOSOME 5Q; CHROMOSOME BAND; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INDUCED DISEASE; EOSINOPHILIC LEUKEMIA; GENE DISRUPTION; GENE FUSION; GENE MAPPING; GENE REARRANGEMENT; GENETIC VARIABILITY; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SKIN MANIFESTATION;

CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 5; EOSINOPHILIA; HUMANS; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TRANSLOCATION, GENETIC;

EID: 0036202529     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046641     Document Type: Review

References (77)

1. Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils: A non-random association
2. Clinical, morphological, cytogenetic and molecular aspects of a series of Ph-negative chronic myeloid leukemias
3. Translocation t(5;12)(q31-q33;p12-p13): A non-random translocation associated with a myeloid disorder with eosinophilia
4. Atypical chronic myelomonocytic leukemia with eosinophilia and translocation (5;12). A new association
5. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
6. Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: Clinical, immunological and cytogenetical features and therapeutic approach
7. Molecular characterization of 12p abnormalities in hematologic malignancies: Deletion of KIP1, rearrangement of TEL, and amplification of CCND2
8. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome
9. Myelodysplastic syndrome associated with increased bone marrow fibrosis and translocation (5;12)(q33;p12.3)
10. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): Comparison with Ph+ CML and chronic myelomonocytic leukemia
11. Myelodysplastic syndrome with t(5;12)(q31; p12-p13) and eosinophilia: A pediatric case with review of literature
12. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion
13. Heterogeneity in the breakpoints in balanced rearrangements involving band 12p13 in hematologic malignancies identified by fluorescence in situ hybridization: TEL (ETV6) is involved in only one half
14. KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12
15. t(5;12)(q31; p12). A clinical entity with features of both myeloid leukemia and chronic myelomonocytic leukemia
16. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia
17. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13)
18. Late appearance of t(5;12)(q31; p12) in acute myeloid leukemia associated with eosinophilia
19. Eosinophilic leukaemia with an abnormality of 5q31, the site of the IL-5 gene
20. t(5;12)(q31;p13): A distinct chronic myeloproliferative disorder (CMPD) with marrow eosinophilia
21. A new subtype of pre-B acute lymphoblastic leukemia with t(5;12)(q31q33;p12), molecularly and cytogenetically distinct from t(5;12) in chronic myelomonocytic leukemia
22. The TEL/ETV6gene is required specifically for hematopoiesis in the bone marrow
23. A myeloproliferative disease in two infants associated with eosinophilia and chromosome t(1;5) translocation
24. Eosinophilic leukaemia with a t(2;5) (p23;q35) translocation
25. A t(3;5) in blastic phase of a Philadelphia chromosome-negative chronic myeloid leukemia
26. t(3;5)(q21;q31) in a myelodysplastic syndrome
27. Morphologic, immunologic, and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: A report from the Children's Cancer Group
28. t(3;5)(q25; q33) in myelodysplastic syndrome
29. Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome 3 abnormality in childhood myeloproliferative disorders
30. Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFbetaR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2)
31. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21)
32. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22)
33. Eosinophilic leukemia with chromosomal aberration t(5;12)(q31;q13): An evidence of the existence of chronic eosinophilic leukemia as a distinct myeloproliferative entity
34. A case of myelodysplasia with eosinophilia having a translocation t(5;12) (q31;q13) restricted to myeloid cells but not involving eosinophils
35. A case of chronic myeloid leukemia without Ph1 translocation
36. Acute myeloblastic leukemia (M2) with translocation (7;11) followed by marked eosinophilia and additional abnormalities of chromosome 5
37. Acute myelogenous leukemia (FAB M1) associated with t(5;16) and eosinophilia. Report of an additional case
38. Acute myelomonocytic leukemia type M4 with bone marrow eosinophilia and t(5;16)(q33; q22)
39. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia
40. A group of previously not recognized cytogenetic abnormalities in myeloid hematological malignancies
41. Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution
42. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1
43. The human GRAF gene is fused to MLL in a unique t(5;11)(q31;q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q
44. AF5q31, a newly identified AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia with ins(5;11)(q31;q13q23)
45. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia
46. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31; p13)
47. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene
48. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome
49. Transcription mapping of the 5q- syndrome critical region: Cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs
50. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
51. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33
52. Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor: Evidence for more than one receptor class
53. A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation
54. Platelet-derived growth factor receptor signals
55. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor
56. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor
57. PDGF-D, a new protease-activated growth factor
58. Genomic organization of the human c-kit gene: Evolution of the receptor tyrosine kinase subclass III
59. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit
60. Cellular distribution of platelet-derived growth factor, transforming growth factor-beta, basic fibroblast growth factor, and their receptors in normal bone marrow
61. Platelet-derived growth factor β receptor regulates interstitial fliud homeostasis through phosphatidylinositol-3′ kinase signaling
62. Signal transduction via platelet-derived growth factor receptors
63. Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains
64. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation
65. The molecular biology of chronic myeloid leukemia
66. Detection of activated platelet-derived growth factor receptors in human meningioma
67. Antisense oligonucleotide inhibition of PDGFR-beta receptor subunit expression directs suppression of intimal thickening
68. The Tel-PDGFRBeta fusion gene produces a chronic myeloproliferative syndrome in transgenic mice
69. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581
70. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor
71. TEL/PDGF-betaR fusion protein activates STAT1 and STAT5: A common mechanism for transformation by tyrosine kinase fusion proteins
72. ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5
73. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
74. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
75. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
76. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
77. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia